Geert O Janssens1, Johannes A Langendijk2, Chris H Terhaard3, Patricia A Doornaert4, Piet van den Ende5, Martin A de Jong6, Robert P Takes7, Paul N Span8, Johannes H Kaanders8. 1. Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: g.o.r.janssens@umcutrecht.nl. 2. Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. 3. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. 4. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 5. Department of Radiation Oncology (MAASTRO), Maastricht University Medical Centre, The Netherlands. 6. Department of Clinical Oncology, Leiden University Medical Centre, The Netherlands. 7. Department of Oto-Rhino-Laryngology and Head & Neck Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands. 8. Department of Radiation Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
BACKGROUND/ PURPOSE: To report on health-related quality-of-life (HRQoL) of patients with laryngeal cancer, treated in a randomized trial comparing accelerated radiotherapy with carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR). MATERIAL/ METHODS: HRQoL was assessed using the HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, and 24months post-baseline. RESULTS:From 269/345 patients (AR: 136/174; ARCON: 133/171) data on HRQoL were available for analysis. Moderate to severe clinical impact of the treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 between baseline and end-of-treatment. At 6months, scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/smell. No difference between AR and ARCON was observed. At 2years from baseline, the percentage of patients reporting moderate to severe complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively, while the majority of patients had no or few complaints of swallowing (79%) or speech (64%). CONCLUSIONS: With accelerated radiotherapy, high local tumor control was obtained while maintaining good speech and swallowing function. Long-term dry mouth, sticky saliva and changes in taste/smell are limited to one quarter of patients. (ClinicalTrials.gov number, NCT00147732).
RCT Entities:
BACKGROUND/ PURPOSE: To report on health-related quality-of-life (HRQoL) of patients with laryngeal cancer, treated in a randomized trial comparing accelerated radiotherapy with carbogen and nicotinamide (ARCON) against accelerated radiotherapy alone (AR). MATERIAL/ METHODS: HRQoL was assessed using the HRQoL Questionnaire-C30 (QLQ-C30) and the Head & Neck cancer module (QLQ-H&N35) at baseline, at completion of radiotherapy and at 6, 12, and 24months post-baseline. RESULTS: From 269/345 patients (AR: 136/174; ARCON: 133/171) data on HRQoL were available for analysis. Moderate to severe clinical impact of the treatment was observed for nearly all items of the QLQ-C30 and QLQ-H&N35 between baseline and end-of-treatment. At 6months, scores returned to baseline level with exception of dry mouth, sticky saliva, and taste/smell. No difference between AR and ARCON was observed. At 2years from baseline, the percentage of patients reporting moderate to severe complaints of dry mouth, sticky saliva, or changes in taste/smell was 30%, 22% and 18%, respectively, while the majority of patients had no or few complaints of swallowing (79%) or speech (64%). CONCLUSIONS: With accelerated radiotherapy, high local tumor control was obtained while maintaining good speech and swallowing function. Long-term dry mouth, sticky saliva and changes in taste/smell are limited to one quarter of patients. (ClinicalTrials.gov number, NCT00147732).
Authors: Linda Spiegelberg; Ruud Houben; Raymon Niemans; Dirk de Ruysscher; Ala Yaromina; Jan Theys; Christopher P Guise; Jeffrey B Smaill; Adam V Patterson; Philippe Lambin; Ludwig J Dubois Journal: Clin Transl Radiat Oncol Date: 2019-01-18
Authors: Hesham Elhalawani; Carlos E Cardenas; Stefania Volpe; Souptik Barua; Sonja Stieb; Calvin B Rock; Timothy Lin; Pei Yang; Haijun Wu; Jhankruti Zaveri; Baher Elgohari; Lamiaa E Abdallah; Amit Jethanandani; Abdallah S R Mohamed; Laurence E Court; Katherine A Hutcheson; G Brandon Gunn; David I Rosenthal; Steven J Frank; Adam S Garden; Arvind Rao; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2021-06-06
Authors: Sonja Stieb; Abdallah S R Mohamed; Tanaya S Deshpande; Jared Harp; Benjamin Greiner; Adam S Garden; Ryan P Goepfert; Richard Cardoso; Renata Ferrarotto; Jack Phan; Jay P Reddy; William H Morrison; David I Rosenthal; Steven J Frank; C David Fuller; G Brandon Gunn Journal: Clin Transl Radiat Oncol Date: 2020-03-24